ESR1 and breast carcinoma: Tamoxifen, widely used in the treatment of ERα+ breast cancer, inhibits the expression of the cell cycle- and apoptosis-related genes targeted by ERα [15, 39]; therefore, ERα could be considered as the principal biomarker for response to tamoxifen treatment in HPV+ OPSCC, similar to that in breast cancer.